for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CytomX Therapeutics Inc

CTMX.OQ

Latest Trade

8.41USD

Change

-0.11(-1.29%)

Volume

184,281

Today's Range

8.39

 - 

8.67

52 Week Range

3.60

 - 

15.43

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.52
Open
8.60
Volume
184,281
3M AVG Volume
14.54
Today's High
8.67
Today's Low
8.39
52 Week High
15.43
52 Week Low
3.60
Shares Out (MIL)
45.92
Market Cap (MIL)
386.21
Forward P/E
-7.90
Dividend (Yield %)
--

Next Event

CytomX Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Cytomx Therapeutics Says Co And Astellas Announce Strategic Collaboration

Cytomx Therapeutics Announces Appointment Of Carlos Campoy As Chief Financial Officer

Cytomx Therapeutics Says May Offer And Sell Shares Of Common Stock Having Offering Price Of Up To $75 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

Industry

Biotechnology & Drugs

Contact Info

151 Oyster Point Blvd Ste 400

SOUTH SAN FRANCISCO, CA

94080-1910

United States

+1.650.5153185

http://cytomx.com/

Executive Leadership

Sean A. McCarthy

Chairman of the Board, President, Chief Executive Officer

Carlos Campoy

Chief Financial Officer, Senior Vice President

Amy C. Peterson

Executive Vice President, Chief Development Officer

W. Michael Kavanaugh

Senior Vice President, Chief Scientific Officer and Head - Research and Non-Clinical Development

Lloyd A. Rowland

Senior Vice President, Chief Compliance Officer, General Counsel, Secretary

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-1.160

2018

-2.030

2019

-2.260

2020(E)

-1.064
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.98
Price To Book (MRQ)
5.54
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-22.36
Return on Equity (TTM)
-17.23

Latest News

Latest News

BRIEF-Cytomx Therapeutics Announces Preclinical Data From Anti-Ctla-4 Probody Therapeutic Programs

* CYTOMX THERAPEUTICS ANNOUNCES PRECLINICAL DATA FROM ANTI-CTLA-4 PROBODY THERAPEUTIC PROGRAMS PRESENTED BY PARTNER BRISTOL MYERS SQUIBB AT AACR ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Cytomx Therapeutics Announces Details Of Presentations At ASCO20

* CYTOMX THERAPEUTICS ANNOUNCES DETAILS OF PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ASCO20 VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Cytomx Therapeutics Appoints Halley E. Gilbert To Board

* CYTOMX THERAPEUTICS APPOINTS HALLEY E. GILBERT TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-CytomX Therapeutics Says To Temporarily Pause New Patient Enrollment, New Site Activation In Proclaim-Cx-2009-001 Study

* CYTOMX THERAPEUTICS ANNOUNCES MILESTONE ACHIEVEMENT IN ABBVIE CD71 PARTNERSHIP AND PROVIDES UPDATE ON IMPACT OF COVID-19 ON CLINICAL STAGE PIPELINE

BRIEF-Cytomx Therapeutics Says Co And Astellas Announce Strategic Collaboration

* CYTOMX THERAPEUTICS AND ASTELLAS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP PROBODY® T-CELL ENGAGING BISPECIFIC THERAPIES FOR TREATMENT OF CANCER

BRIEF-Cytomx Therapeutics Announces Appointment Of Carlos Campoy As Chief Financial Officer

* CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER

BRIEF-Cytomx Therapeutics Says May Offer And Sell Shares Of Common Stock Having Offering Price Of Up To $75 Million

* CYTOMX THERAPEUTICS INC - MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UP TO $75 MILLION FROM TIME TO TIME Source: (https://bit.ly/32vK9iE) Further company coverage:

BRIEF-Bristol-Myers Squibb Advances Cytomx Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 Into Randomized Cohort Expansion Of Ongoing Clinical Trial

* BRISTOL-MYERS SQUIBB ADVANCES CYTOMX THERAPEUTICS’ ANTI-CTLA-4 PROBODY THERAPEUTIC BMS-986249 INTO RANDOMIZED COHORT EXPANSION (PART 2A) OF ONGOING CLINICAL TRIAL

BRIEF-CytomX Therapeutics Q1 Revenue $14.2 Mln Vs I/B/E/S View $16.4 Mln

* CYTOMX THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cytomx Therapeutics Provides Operational Update

* CYTOMX THERAPEUTICS ANNOUNCES FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

BRIEF-Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8

* PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING Source text (http://bit.ly/2BGceJ2) Further company coverage:

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC

BRIEF-CytomX reports Q3 loss per share $‍0.28​

* CytomX announces third quarter 2017 financial results and operational progress

BRIEF-CytomX Therapeutics appoints Charles Fuchs to board of directors

* CytomX Therapeutics Inc appoints Charles S. Fuchs, M.D., MPH to board of directors Source text for Eikon: Further company coverage:

BRIEF-Cytomx Therapeutics Q2 loss per share $ 0.69​

* Cytomx announces second quarter 2017 financial results and mid-year update webcast conference call

BRIEF-Canaan IX LP dissolves passive stake in Cytomx Therapeutics as of June 7 - SEC filing

* Canaan IX LP dissolves passive stake in Cytomx Therapeutics Inc as of June 7 - SEC filing

BRIEF-BVF Partners LP reports 5.5 pct passive stake in CytomX Therapeutics as of June 19 - SEC Filing

* BVF Partners LP reports 5.5 percent passive stake in CytomX Therapeutics Inc as of June 19 - SEC Filing Source text: [http://bit.ly/2trugL5] Further company coverage:

BRIEF-CytomX achieves development milestone in collaboration with AbbVie

* CytomX achieves development milestone in strategic oncology collaboration with AbbVie for CD71-targeting probody drug conjugate

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up